EN
There are different branches of the sensogenomics project. One of them has to do with gene expression after receiving musical stimuli. Several nice successful milestones, 3 experimental concerts, where biological samples were collected before and after a classical musical concert:
For the honor and scientific committee of sensogenomics, please, visit our WEBSITE sensogenomics.
And follow us on TWITTER (@sensogenomics) and INSTRAGRAM(@sensogenomics.
See also the VIDEO insight and the English version of SENSOGENOMICS
Respiratory syncytial virus (RSV) is highly contagious and affects the lungs and airways. RSV infection exhibits a seasonal pattern, and the clinical presentation varies from typical flu-like symptoms to severe respiratory disease in young children and older adults. To avoid life-threatening RSV complications, there is an imminent need to introduce an RSV vaccine into national immunization programs. The EU-funded PROMISE project will undertake epidemiological analyses by collecting data from national registries and systematic reviews, and will validate new RSV infection biomarkers. The establishment of an EU-wide RSV surveillance system alongside the post-marketing monitoring and evaluation of the RSV vaccines in advanced clinical development will provide further evidence for the safety and efficacy of RSV immunization.
The goals of DIAMONDS are: 1) Incorporate Personalized Medicine (PM) into routine practice through an innovative diagnostic approach to one of the most common healthcare challenges: the management of febrile illnesses with non-specific symptoms, which accounts for a third of healthcare interventions; 2) A new PM approach for the diagnosis of infectious and inflammatory diseases based on individual RNA signatures detected in blood and demonstrate the benefit of this approach to individuals and healthcare systems and its economic viability; 3) Achieving a paradigm shift from diagnosis based on clinical signs and symptoms and imperfect testing to a new PM method for rapid and accurate diagnosis based on each individual's blood gene expression pattern. In this regard, the consortium believes that a new molecular classification of infectious and inflammatory diseases will ultimately be more accurate than current clinical classifications, enabling faster diagnosis and treatment, reducing healthcare costs, and improving patient safety and satisfaction.
RESCEU’s vision is to integrate and exploit existing knowledge and data to provide greater insights into the impact of RSV on health systems and societies throughout Europe, and to actively engage stakeholders in order to improve strategic planning and decision-making. It also seeks to access existing clinically annotated biological specimens from prospective studies and to supplement this with bespoke clinical studies to create a powerful new bio-repository for future research. RESCEU will establish a pan-European multi-stakeholder community of academia, public health bodies, scientific societies, patient organizations, regulatory agencies and the private sector, including pharmaceuticals and SMEs.
c4c (conect4children) is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire pediatric population. It is a pioneering opportunity to build capacity for the implementation of multinational pediatric clinical trials whilst ensuring the needs of babies, children, young people and their families are met.
The project is committed to meeting the needs of pediatric patients thanks to a novel collaboration between the academic and the private sectors, which includes 35 academic and 10 industry partners and around 500 affiliated partners. c4c endeavors to provide a sustainable, integrated platform for the efficient and swift delivery of high quality clinical trials in children and young people across all conditions and phases of the drug development process. c4c strives to bring innovative processes to all stages of clinical development by generating a new model of organization and of the clinical development process. By emphasizing inclusiveness and collaboration across geographical, specialty, sectoral, cultural and societal backgrounds, it will set up a new infrastructure to support all evaluations of medicines in children. In this manner, it will become a benchmark in the currently fragmented European clinical research environment. Best practices and up-to-date expert advice will inform the c4c approaches and methods, which will subsequently be refined in the context of viability trials.
ZIKAction proposes to set up a multidisciplinary research network across Latin America with a focus on maternal and child health to coordinate and implement urgent research against the current ZIKV outbreak and lay the foundation for a preparedness research network against future emerging severe infectious threats in vulnerable populations. ZIKAction will assess ZIKV-related complications, as well as risk factors and mechanisms of vertical transmission of the disease.
The aim of the PERFORM project is to improve diagnosis and management of febrile children, by applying sophisticated transcriptomic, proteomic and bioinformatics approaches to well characterized large-scale, multi-national patient cohorts already recruited with EU funding. Identify promising and personalized new discriminators of bacterial and viral infection including transcriptomic and clinical phenotypic markers that can be used to develop simple, personalized, point-of-care testing. Evaluation of the current management of febrile illnesses in Europe using quantitative and qualitative methods (including cost-effectiveness analysis) to choose the best management strategies based on our new evidence in different healthcare settings across Europe. The most accurate tests and approaches distinguishing bacterial and viral infection will be evaluated in prospective cohorts of patients reflecting the different health care settings across Europe to provide the evidence needed for European and international healthcare systems to adopt our new management plan for febrile patients.
The aim of the PoC-ID project is to develop new micro- and nanoelectronic-based sensing and integration concepts for advanced miniaturized in vitro diagnostic devices. PoC-ID will combine the detection of both pathogens and host responses leading to more accurate diagnosis as compared to the current standard, which is focused on detection of pathogens only. This novel approach will support prevention and control of pathogen spread and enable faster and more personalized patient treatment. The main objective of the study is to evaluate and validate integrated sensor technologies with clinical samples.
The CRICOV19 is a technique is based on the CRISPR-Cas12 assay to detect SARS-CoV-2. The aim is to develop a rapid competitive test to detect the reference sequence (that belongs to the SARS-CoV-2 N gene) in a few minutes, providing a low-cost alternative with virtually no need for specific equipment. Another aim is to improve the specificity of the method by adding additional specific and conserved sequences of the SARS-CoV-2 genome and to evaluate this rapid CRISPR-Cas12 test in different clinical scenarios and patient populations.
The aim of the PREPARE project is to transform Europe’s response to future severe epidemics or pandemics by providing infrastructure, co-ordination and integration of existing clinical research networks, both in community and hospital settings. It represents a new model of collaboration and will provide a one-stop shop for policy makers, public health agencies, regulators and funders of research into pathogens with epidemic potential. It will do this by mounting interepidemic (‘peace time’) patient oriented clinical trials in children and in adults, investigations of the pathogenesis of relevant infectious diseases and facilitate the development of sophisticated state-of-the-art near-patient diagnostics.
Despite significant advances in the prevention and control of bacterial infectious diseases in childhood, mainly with antibiotics and vaccines, many children are hospitalized as a result of these diseases, which may cause death or significant sequelae. For this reason, further research is needed to better understand how children's bodies respond to these infections in order to develop new treatments, find new ways to identify children at higher risk of disease, and improve prevention measures. There is increasing evidence that genetic factors are key in determining the risk of infection, and the ability to combat it, both spontaneously and after vaccination. The primary objective of this project is to identify which genes determine whether a child will have a higher risk of infection, or death or sequelae, as a result of the infection, as well as whether or not a child will respond well to vaccination.
Every 50 seconds a child dies as a result of rotavirus infection. We know now that repeated exposure to rotavirus, either naturally or after vaccination, provides protection against the virus. However, the mechanisms involved are barely known. Serum anti-rotavirus immunoglobulin A (IgA) is the best marker of protection against rotavirus. However, it is not used in routine practice, and it does not correlate well with clinical protection. The aim of this project is to implement a whole 'omics' approach (integrated application of 'omics' sciences) to evaluate the response to rotavirus, both after natural infection (immunogenomics) or vaccination (vaccinomics), in order to better understand the immunity of the disease and to identify new biomarkers of protection. Finding an accurate and reproducible biomarker of protection would not only be a milestone in the study of the disease, but would also have an immediate impact on the implementation of currently available vaccines and on the evaluation and development of new rotavirus vaccines.
SARS-COV-2 presents with mild to fatal clinical phenotypes, and has a differential impact on pediatric patients that may be the key in the fight against the disease. Our experience in host genomics and transcriptomics in infectious diseases suggests that human host genetics may contribute to explaining the differential patterns of SARS-COV-2 in different subjects and age groups. By applying the infectomics approach - study of DNA, RNA and serum of pediatric and adult patients with different severity - the aim is to detect soluble immune biomarkers to characterize the immune response to SARS-COV-2, as well as to identify susceptibility and prognosis genetic markers for COVID-19 in order to find new therapeutic targets, establish diagnosis-prognosis based on specific transcriptomic fingerprints and to prescribe personalized therapeutic or preventive measures.
The large amount of SARS-CoV-2 genome data generated worldwide and available in public repositories (n>40,000) offers a unique opportunity to conduct a detailed study to assess the impact of outbreaks on the genomic variability of the virus and its mechanism of spread. This project conducted a thorough phylogenetic characterization of SARS-CoV-2 using these sequences, but also the geographical mapping of the viral haplotypes that are spread worldwide. This will allow us to study in detail the patterns of phylogeographic variability of the virus, to make inferences about the origin of the pandemic and to study the dynamics of the spread of the different viral strains, both globally and more locally (in Spain and Galicia). In addition, a publicly available web-based tool was created to classify and analyze variability based on the constructed phylogeny. The project data will help to adopt the necessary to prevent and predict outbreaks of this pandemic and to trace new cases, as well as to be better prepared to face a potential new wave of the pandemic. Knowing the evolution and distribution patterns of the different viral lineages will also help to adopt the necessary to prevent and predict new outbreaks of this pandemic, as well as to be better prepared to face a new potential pandemic. Similarly, the analysis of the genomic variability of SARS-CoV-2 would also be extremely useful for the design of future vaccines against COVID-19 and diagnostic tests for SARS-CoV-2.
DIAVIR aims to improve the diagnosis and treatment of febrile patients as well as to reduce the use of antibiotics in clinical practice by using a proprietary transcriptomic biomarker signature (EP19382084.2), which is the result of sophisticated bioinformatics approaches, and by evaluating it in the context of our previous findings (Herberg et al. 2016; JAMA) in partnership with Mike Levin of Imperial College, a partner also on this occasion. The project will analyze samples from children recruited by the national clinical network (GENDRES; 26 national hospitals and 15 primary care centers) and the PERFORM network, both coordinated by our group, and the 12 de Octubre Hospital, led by Dr. Pablo Rojo, will be a recruiting center. The project will enroll children affected by viral or bacterial infection with different severities.. Samples will be analyzed using high-throughput transcriptomics (NanoString) and a qPCR protocol will be defined to ease the implementation in health centers. A special effort will be made to develop a point-of-care test based on state-of-the-art technology (mini RNAseq; Flongle) and non-invasive samples.
The main purpose of the project is to advance knowledge of host molecular factors associated with RSV infection and disease using a multidisciplinary omics approach and non-invasive samples. This approach will help to open new paths for personalized disease management, early recognition and prevention, and selective treatment of infected patients. We will use an innovative approach to find diagnostic and prognostic biomarkers based on molecular phenotyping of non-invasive samples obtained from the nasal epithelium and oral mucosa, and the subsequent bioinformatics analysis of the data. The study integrates data from genomic, epigenetic and transcriptomic studies in hospitalized children with RSV infection and mild to severe disease, and asymptomatic children.
Food Protein Enterocolitis Syndrome (FPIES) is a potentially life-threatening food allergy that affects 1 in 15 children. One of the major problems associated with this condition is that it presents with rather non-specific and unpredictable clinical signs and symptoms, ranging from profuse vomiting and lethargy to hypotension and shock, and differs from the most common form of food allergy i.e. immediate or IgE-mediated allergy. There is a great lack of knowledge about the underlying molecular mechanisms of this condition. In addition, the only reliable clinical procedure to diagnose FPIES is the oral food challenge test (OFC) in which a food is given under medical supervision, to determine if it triggers an allergic reaction. However, this test poses a significant risk for the patient because it is not possible to predict the severity of the reaction, in addition to being expensive.
The main objective of this study is to identify host genetic determinants and genes that control both susceptibility and severity of enterovirus infection using a large-scale genomic approach. To this end, a multidisciplinary omics approach will help to open new paths for personalized disease management, early recognition and prevention, and selective treatment of enterovirus-infected patients. In this study, the Hospital La Paz collaborates with the active recruiting within the ENTEROGEN Network, with Dr. Cristina Calvo (Hospital La Paz) coordinating the sample collection in her center.
The main purpose of BI-BACVIR is to develop a technology based on the host response to infection in order to improve the diagnosis and treatment of febrile children using a sophisticated transcriptomics and bioinformatics approach. Once validated, this approach could be implemented as a protocol in clinical diagnostic laboratories and become a point-of-care test. Using this novel approach, the project aims to accelerate the diagnosis of viral and bacterial diseases thereby reducing the use of antibiotics and thus the emergence of multi-resistant bacteria; to reduce hospital admissions and prevent misdiagnosis; and to reduce the cost of diagnosing infections: cell cultures, lumbar punctures, aspiration procedures, etc.
Progressive Osseous Heteroplasia (POH) is an ultra-rare disease in which extra-skeletal ossification occurs in mesodermal tissue. The genetic alteration is located in the GNAS complex. There is no cure or preventive treatment for this disease and the only solutions are surgical amputation of the affected limbs and well-defined lesions. Our group has been providing care for several years to the only reported case in the world of HOP in identical univitelline twins. We identified a mutation in the GNAS gene in both girls; however, one of them suffers from an unusually rapidly progressive and disabling form of the disease, while the other is asymptomatic. HOPE will use a translational ‘-omics’ approach and a cell model to characterize the disease and identify therapeutic targets to improve the quality of life of patients. Advances in the study of HOP will be key to understanding other related conditions associated with GNAS mutations (Albright's hereditary dystrophy, pseudohypoparathyroidism, primary osteoma cutis, etc.).
This project aims to detect, evaluate and implement clinical, genomic and immune markers of RSV infection using a systems biology approach applied to diagnosis, evolution and prognosis. For this purpose, a novel whole-omics approach for the study of RSV infection will be used. All the groups involved in this project work very closely through the GENDRES Network and other international partnerships.
